AR128217A1 - Composiciones para el tratamiento de e. coli y salmonella - Google Patents

Composiciones para el tratamiento de e. coli y salmonella

Info

Publication number
AR128217A1
AR128217A1 ARP230100036A ARP230100036A AR128217A1 AR 128217 A1 AR128217 A1 AR 128217A1 AR P230100036 A ARP230100036 A AR P230100036A AR P230100036 A ARP230100036 A AR P230100036A AR 128217 A1 AR128217 A1 AR 128217A1
Authority
AR
Argentina
Prior art keywords
salmonella
compositions
coli
treatment
bacteriophages
Prior art date
Application number
ARP230100036A
Other languages
English (en)
Inventor
Soto Nicols Ferreira
Castro Hans Pieringer
Palma Pablo Cifuentes
Zambrano Diego Belmar
Original Assignee
Phagelab Chile Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phagelab Chile Spa filed Critical Phagelab Chile Spa
Publication of AR128217A1 publication Critical patent/AR128217A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere a una composición que comprende una mezcla de al menos dos bacteriófagos, que son útiles para combatir el crecimiento de Escherichia coli STEC y ETEC, y de diferentes serovares de Salmonella, en animales de granja que sufren infecciones por estas bacterias; procesos para producir dichas composiciones; formulaciones estabilizadas que comprenden dichos bacteriófagos; y usos en el control de bacterias enteropatógenas en animales.
ARP230100036A 2022-02-11 2023-01-06 Composiciones para el tratamiento de e. coli y salmonella AR128217A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2022/051257 WO2023152549A1 (en) 2022-02-11 2022-02-11 Compositions for the treatment of e. coli and salmonella

Publications (1)

Publication Number Publication Date
AR128217A1 true AR128217A1 (es) 2024-04-10

Family

ID=87563757

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100036A AR128217A1 (es) 2022-02-11 2023-01-06 Composiciones para el tratamiento de e. coli y salmonella

Country Status (2)

Country Link
AR (1) AR128217A1 (es)
WO (1) WO2023152549A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
EP2462940A1 (en) * 2004-11-02 2012-06-13 Chr. Hansen A/S Stabilized bacteriophage formulations
US11260089B2 (en) * 2014-11-19 2022-03-01 San Diego State University (Sdsu) Foundation Products of manufacture comprising bacteriophages
EP3253215B1 (en) * 2015-01-23 2023-06-14 Intralytix, Inc. Novel shigella bacteriophages and uses thereof
WO2017053327A1 (en) * 2015-09-24 2017-03-30 San Diego State University (Sdsu) Foundation , Dba San Diego State University Research Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them

Also Published As

Publication number Publication date
WO2023152549A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
Du et al. In vitro antibacterial activity of thymol and carvacrol and their effects on broiler chickens challenged with Clostridium perfringens
RU2713182C2 (ru) Антимикробная композиция
PE20220496A1 (es) Metodos innovadores para el tratamiento de las semillas y componentes para mejorar los atributos y el rendimiento de la planta
PE20210924A1 (es) Composiciones para animales, y sus usos
ECSP21071788A (es) Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos
BR112022001344A2 (pt) Combinações de antibióticos beta-lactâmicos administrados por via oral e derivados de avibactam para tratamento de infecções bacterianas
UY39233A (es) Compuestos heterocíclicos como anthelmínticos
Karpiński et al. Antibacterial activity of apigenin, luteolin, and their C-glucosides
AR128217A1 (es) Composiciones para el tratamiento de e. coli y salmonella
BR112022003777A2 (pt) Composições e métodos para controle pagogênico
CO2020010533A2 (es) Novedoso bacteriófago de salmonella heidelberg sal-hep-1 y su uso para inhibir el crecimiento de las bacterias de salmonella heidelberg
US20160157482A1 (en) Antimicrobial Compositions Containing Carvacrol and Thymol
BR112021018854A2 (pt) Estabilização de bactérias mollicutes vivas em uma composição líquida
WO2019098241A1 (ja) 乳房炎用医薬組成物、および治療方法
Wooley et al. In vitro effect of a buffered chelating agent and neomycin or oxytetracycline on bacteria associated with diseases of fish
RU2765284C1 (ru) Способ повышения антибактериальной активности наночастиц серебра в отношении St. aureus
Owain et al. Evaluation the Antimicrobial Effect of Glycerin Magnesia on Some Bacteria, in-Vitro Study
RU2593809C1 (ru) Композиционный препарат для профилактики эшерихиозного гастроэнтерита поросят
Li et al. Research Note: Synergistic effect of isopropoxy benzene guanidine and colistin against mcr-1-positive Escherichia coli in vitro and in duck intestine infection models
Hermans et al. Medium-chain fatty acids and plant-derived antimicrobials to prevent Campylobacter colonization in broiler chickens
AU2017235711B2 (en) Enhanced tulathromycin
Zardoshti et al. Evaluation Of The Effect Of Phosphomycin Along With Thymus Vulgaris Essential Oil On Methicillin Resistant Staphylococcus Aureus
Borges et al. Activity of allylisothiocyanate and 2-phenylethylisothiocyanate on motility and biofilm prevention of pathogenic bacteria
CO2024005447A2 (es) Compuestos de pirrolopiridazina como antihelmínticos
Rayamajhi et al. An evaluation on rainbow trout (Oncorhynchus mykiss) diseases and their control measures in Nepal